Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -281.14% is 578% below its 5-year average of -41.49%, near the low end of its 5-year range (-281.14%–-18.93%).
As of the fiscal period ended Tuesday, June 30, 2026. 71.29% below its 12-month average of -164.13%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2027 (2026-06-30): -281.14%.
RETURN ON EQUITY (ROE)
-281.14%
RETURN ON EQUITY (ROE) AVG TTM
-164.13%
RETURN ON EQUITY (ROE) AVG 3Y
-78.26%
RETURN ON EQUITY (ROE) AVG 5Y
-41.49%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-71.29%
CURRENT VS 3Y AVG
-259.22%
CURRENT VS 5Y AVG
-577.61%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 753 covered companies
CURRENT VS SECTOR MEDIAN
-569.23%
vs the sector median at left
Replimune Group, Inc.
Market Cap
$1.11B
Return on Equity (ROE)
-281.14%
TTM Avg
-164.13%
3Y Avg
-78.26%
5Y Avg
-41.49%
Market Cap
$1.11B
Return on Equity (ROE)
-48.56%
TTM Avg
-84.22%
3Y Avg
-65.23%
5Y Avg
-44.45%
Market Cap
$1.10B
Return on Equity (ROE)
1.05%
TTM Avg
-23.37%
3Y Avg
-7.64%
5Y Avg
-0.10%
Market Cap
$1.13B
Return on Equity (ROE)
N/A
TTM Avg
35.70%
3Y Avg
35.70%
5Y Avg
35.70%
Market Cap
$1.13B
Return on Equity (ROE)
-244.91%
TTM Avg
-17.45%
3Y Avg
-30.16%
5Y Avg
-48.76%
Market Cap
$1.10B
Return on Equity (ROE)
-57.77%
TTM Avg
-49.78%
3Y Avg
-41.82%
5Y Avg
-41.82%
Market Cap
$1.13B
Return on Equity (ROE)
2.51%
TTM Avg
3.60%
3Y Avg
0.50%
5Y Avg
-7.05%
Market Cap
$1.09B
Return on Equity (ROE)
-6.16%
TTM Avg
-10.85%
3Y Avg
-14.08%
5Y Avg
-9.38%
Market Cap
$1.09B
Return on Equity (ROE)
-39.54%
TTM Avg
-24.09%
3Y Avg
36.77%
5Y Avg
36.77%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Replimune Group, Inc. (REPL) | $1.11B | -281.14% | -164.13% | -78.26% | -41.49% |
| Tandem Diabetes Care, Inc. (TNDM)vs › | $1.11B | -48.56% | -84.22% | -65.23% | -44.45% |
| STAAR Surgical Company (STAA)vs › | $1.10B | 1.05% | -23.37% | -7.64% | -0.10% |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.13B | N/A | 35.70% | 35.70% | 35.70% |
| Harrow Health, Inc. (HROW)vs › | $1.13B | -244.91% | -17.45% | -30.16% | -48.76% |
| First Tracks Biotherapeutics Inc (TRAX)vs › | $1.10B | -57.77% | -49.78% | -41.82% | -41.82% |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.13B | 2.51% | 3.60% | 0.50% | -7.05% |
| OPKO Health, Inc. (OPK)vs › | $1.09B | -6.16% | -10.85% | -14.08% | -9.38% |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.09B | -39.54% | -24.09% | 36.77% | 36.77% |
| IRadimed Corporation (IRMD)vs › | $1.08B | 22.66% | 22.95% | 21.85% | 17.09% |
ROE
-281.1%
ROA
-117.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -281.14% |
| 2026-03-31 | -188.94% |
| 2025-12-31 | -149.55% |
| 2025-09-30 | -117.82% |
| 2025-06-30 | -83.22% |
| 2025-03-31 | -59.47% |
| 2024-12-31 | -47.32% |
| 2024-09-30 | -55.84% |
| 2024-06-30 | -51.59% |
| 2024-03-31 | -57.62% |
| 2023-12-31 | -49.81% |
| 2023-09-30 | -42.68% |
| 2023-06-30 | -35.33% |
| 2023-03-31 | -31.39% |
| 2022-12-31 | -26.33% |
| 2022-09-30 | -38.20% |
| 2022-06-30 | -32.41% |
| 2022-03-31 | -28.70% |
| 2021-12-31 | -24.65% |
| 2021-09-30 | -21.85% |
| 2021-06-30 | -18.93% |
| 2021-03-31 | -16.22% |
| 2020-12-31 | -14.56% |
| 2020-09-30 | -26.61% |
| 2020-06-30 | -21.82% |
| 2020-03-31 | -28.64% |
| 2019-12-31 | -22.01% |
| 2019-09-30 | -28.99% |
| 2019-06-30 | -23.28% |
| 2019-03-31 | -22.37% |
| 2018-12-31 | -21.66% |
| 2018-09-30 | -18.47% |
| 2017-12-31 | -24.98% |
